NASDAQ · Biotechnology · USD
Ensysce Biosciences, Inc. (ENSC) Stock Analysis
Ensysce Biosciences, Inc. (ENSC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ENSC Key Statistics
As of Sep 4, 2026Trading
- Open
- $0.44
- Previous Close
- $0.44
- Day's Range
- 0.41–0.46
- 52-Week Range
- 0.23–2.75
- Volume
- 530.40K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.98
Valuation
- Market Cap
- $8.87M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 1.97
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −2.56
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$10.18M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −280.48%
- Shares Outstanding
- 19.46M
- 1-Year Return
- −78.79%
Dividend and dates
- Avg Volume
- 14.80M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
ENSC Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −50.43% |
| 2025 | −88.70% |
| 2024 | −48.81% |
| 2023 | −88.22% |
| 2022 | −99.20% |
| 2021 | −62.20% |
| 2020 | +19.34% |
| 2019 | +6.11% |
| 2018 (partial year) | +2.83% |
As of September 4, 2026.
ENSC Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$10.18M | — |
| 2024 | $0.00 | −$7.99M | — |
| 2023 | $0.00 | −$10.61M | — |
| 2022 | $0.00 | −$24.17M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$10.24M | −$10.18M | — |
| 2024 | $0.00 | — | −$6.73M | −$7.99M | — |
| 2023 | $0.00 | — | −$10.72M | −$10.61M | — |
| 2022 | $0.00 | — | −$24.22M | −$24.17M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
ENSC Valuation vs Biotechnology Median
Median of 656 stocks| Metric | ENSC | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 1.97 | 15.26 | 0.1x the median |
| Profit margin | −280.48% | 0.00% | 280.5 pts below |
Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
Ensysce Biosciences Completes Enrollment In Final Stage Of PF614-MPAR-102 Clinical Study
BenzingaEnsysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financing Prepared Remarks Transcript
SeekingAlphaEnsysce Biosciences Q2 EPS $(0.20) Beats $(0.50) Estimate, Sales $1.164M Beat $1.000M Estimate
BenzingaEnsysce Biosciences Completes Acquisition Of Cy Biopharma, Secures $17.1M Cash Financing And $21.5M Series C Preferred Stock Private Placement With Potential $38.6M Follow-On Tranche To Fund CY200 Development Through 2028
BenzingaEnsysce Biosciences Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF".
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$138.42B
REGNRegeneron Pharmaceuticals, Inc.
$85.22B
ARGXargenx SE
$64.25B
MRNAModerna, Inc.
$58.11B
RVMDRevolution Medicines, Inc.
$45.01B
ONCBeOne Medicines AG
$40.53B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B